Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
A Phase 2/3 Open-label, Randomized, Sequential Dose Escalation Cohort Study of T2307 Versus Standard of Care in Treatment of Subjects with Candidemia due to Candida Auris and other Drug-resistant Candida Species: An Adaptive Design Study
Grant
Overview
Affiliation
Overview
Awarded By
National Institute of Allergy and Infectious Diseases/NIH/DHHS
Total Award Amount
222750.00
Direct Costs
151143.00
Sponsor Award Id
R34AI150517
Affiliation
Contributor
Gerald McGwin
Investigator
Peter Pappas M.D.
Principal Investigator
Todd McCarty
Investigator